v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 29, 2025
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     $ 1,910  
Provision [2] $ 419 $ (74) 468 $ 547
Utilization and other [3]     (695)  
Balance, ending [4] 1,682   1,682  
Balance Sheet Location [Axis]: us-gaap:OtherLiabilitiesCurrent        
Restructuring Reserve [Roll Forward]        
Balance, beginning     1,400  
Balance, ending 972   972  
Balance Sheet Location [Axis]: us-gaap:OtherLiabilitiesNoncurrent        
Restructuring Reserve [Roll Forward]        
Balance, beginning     466  
Balance, ending 710   710  
Employee Termination Costs [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     1,783  
Provision     369  
Utilization and other [3]     (577)  
Balance, ending [4] 1,575   1,575  
Asset Impairment Charges [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     0  
Provision     82  
Utilization and other [3]     (82)  
Balance, ending [4] 0   0  
Exit Costs [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     127  
Provision     17  
Utilization and other [3]     (36)  
Balance, ending [4] $ 107   $ 107  
[1] Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($466 million).
[2] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $390 million for the three months ended June 28, 2026 (including charges of $417 million for our Realigning our Cost Base Program and credits of $29 million for our Manufacturing Optimization Program), (ii) charges of $421 million for the six months ended June 28, 2026 (including charges of $464 million for our Realigning our Cost Base Program and credits of $52 million for our Manufacturing Optimization Program), (iii) credits of $406 million for the three months ended June 29, 2025 (including credits of $408 million for our Manufacturing Optimization Program and $25 million for our Realigning our Cost Base Program) and (iv) charges of $211 million for the six months ended June 29, 2025 (including charges of $562 million for our Realigning our Cost Base Program and credits of $412 million for our Manufacturing Optimization Program). For 2025, Employee terminations included revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.
[3] Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
[4] Included in Other current liabilities ($972 million) and Other noncurrent liabilities ($710 million).